• Horizon Discovery Ltd., of Cambridge, UK, said it is collaborating with the Rosalind Franklin University of Medical Sciences to develop a human cellular disease model of cystic fibrosis. The agreement focuses on the use of Horizon's GENESIS precision genome editing technology to reconstitute a specific mutation in the cystic fibrosis transmembrane conductance regulatory protein.